Bionova CSO Jesse McCool, PhD, will discuss the strategies and technologies Bionova is leveraging to assist early-stage biologics innovators in bridging the chasm between discovery and Phase 1. Dr. McCool will discuss specific advances, such as Bionova’s upgraded cell line development platform, which is drastically reducing CLD timelines. He will also describe how Bionova intentionally co-located and integrated all pre-GMP activities under one roof. This approach is yielding meaningful technical and efficiency gains as process development teams facilitate seamless technology transfer by scaling and training simultaneously.
.jpg?fid=912933)
